Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus

Oliver von Kampen, Stephan Buch, Michael Nothnagel, Lorena Azocar, Hector Molina, Mario Brosch, Wiebke Erhart, Witigo von Schönfels, Jan Egberts, Marcus Seeger, Alexander Arlt, Tobias Balschun, Andre Franke, Markus M. Lerch, Julia Mayerle, Wolfgang Kratzer, Bernhard O.

Exception point applications for 15 points: An unintended consequence of the Share 15 policy

Therese Bittermann, George Makar, David Goldberg – 16 August 2012 – In 2005, the United Network for Organ Sharing (UNOS) adopted the Share 15 policy to improve organ allocation by facilitating transplantation for local and regional patients with Model for End‐Stage Liver Disease (MELD) scores of 15 or higher. There has been concern that the lack of standardization in the use of exception points is potentially diminishing the benefits of this policy.

Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR

Vincent W. Keng, Daniela Sia, Aaron L. Sarver, Barbara R. Tschida, Danhua Fan, Clara Alsinet, Manel Solé, Wai L. Lee, Timothy P. Kuka, Branden S. Moriarity, Augusto Villanueva, Adam J. Dupuy, Jesse D. Riordan, Jason B. Bell, Kevin A. T.Silverstein, Josep M. Llovet, David A. Largaespada – 16 August 2012 – Hepatocellular carcinoma (HCC) is one of the deadliest solid cancers and is the third leading cause of cancer‐related death. There is a universal estimated male/female ratio of 2.5, but the reason for this is not well understood.

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

Tokuzo Arao, Kazuomi Ueshima, Kazuko Matsumoto, Tomoyuki Nagai, Hideharu Kimura, Satoru Hagiwara, Toshiharu Sakurai, Seiji Haji, Akishige Kanazawa, Hisashi Hidaka, Yukihiro Iso, Keiichi Kubota, Mitsuo Shimada, Tohru Utsunomiya, Masashi Hirooka, Yoichi Hiasa, Yoshikazu Toyoki, Kenichi Hakamada, Kohichiroh Yasui, Takashi Kumada, Hidenori Toyoda, Shuichi Sato, Hiroyuki Hisai, Teiji Kuzuya, Kaoru Tsuchiya, Namiki Izumi, Shigeki Arii, Kazuto Nishio, Masatoshi Kudo – 13 August 2012 – The response rate to sorafenib in hepatocellular carcinoma (HCC) is relatively low (0.7%‐3%), however, rapid and d

Subscribe to